Researchers from Children’s Hospital of Philadelphia (CHOP), the University of Iowa and the Rochester School of Medicine and Dentistry were awarded a $858,932 Collaborative Grant today from Emily’s Entourage (EE), an innovative nonprofit that accelerates research for new therapies and a cure for individuals with cystic fibrosis (CF) who don’t benefit from existing treatments.
CF is a genetic disorder caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene that severely affects the lungs, digestive system, and other organs. Significant advancements have been made in CFTR therapies that have greatly improved the quality of life and life expectancy for individuals with CF. However, approximately 10% of individuals with CF still lack effective treatment options.
The newly funded project, "Enhanced Airway Transduction and Therapeutic Cargo Delivery with Novel Adeno-associated Virus (AAV) Capsid Variants,” will be led for CHOP by Beverly Davidson, PhD, Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics and Chief Scientific Strategy Officer at CHOP. Davidson will work collaboratively with scientists across the two other university systems to address barriers to effective treatments through the emergence of new technologies that restore CFTR function to people with CF.
Learn more about the new initiative to accelerate groundbreaking CF research here.
Researchers from Children’s Hospital of Philadelphia (CHOP), the University of Iowa and the Rochester School of Medicine and Dentistry were awarded a $858,932 Collaborative Grant today from Emily’s Entourage (EE), an innovative nonprofit that accelerates research for new therapies and a cure for individuals with cystic fibrosis (CF) who don’t benefit from existing treatments.
CF is a genetic disorder caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene that severely affects the lungs, digestive system, and other organs. Significant advancements have been made in CFTR therapies that have greatly improved the quality of life and life expectancy for individuals with CF. However, approximately 10% of individuals with CF still lack effective treatment options.
The newly funded project, "Enhanced Airway Transduction and Therapeutic Cargo Delivery with Novel Adeno-associated Virus (AAV) Capsid Variants,” will be led for CHOP by Beverly Davidson, PhD, Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics and Chief Scientific Strategy Officer at CHOP. Davidson will work collaboratively with scientists across the two other university systems to address barriers to effective treatments through the emergence of new technologies that restore CFTR function to people with CF.
Learn more about the new initiative to accelerate groundbreaking CF research here.